To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPD) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17/27 patients. Surprisingly, only 5/17 patients developed JAK2-V617F positive AML, whereas 9/17 patients transformed to JAK2-V617F negative AML. Microsatellite analysis in a female patient showed that mitotic recombination was not responsible for the transition from JAK2-V617F positive MPD to JAK2-V617F negative AML, and clonality determined by the MPP1-polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental X-chromosome. In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. We conclude that JAK2-V617F positive MPD frequently yields JAK2-V617F negative AML
Introduction
Myeloproliferative disorders (MPD) are a heterogeneous group of diseases characterized by increased hematopoiesis leading to elevated numbers of non-lymphoid cells and/or platelets in the peripheral blood. An acquired somatic mutation in the JAK2 gene resulting in a valine to phenylalanine substitution at position 617 (JAK2-V617F) is frequently found in patients with MPDs. [1] [2] [3] [4] Using a sensitive allele-specific PCR assay, the JAK2-V617F mutation is detectable in >90% of patients with polycythemia vera (PV), >50% of essential thrombocythemia (ET) and >50% of idiopathic myelofibrosis (IMF). 2, 5, 6 Transformation to AML is a known complication of MPDs. [7] [8] [9] The frequency of JAK2-V617F in patients with de novo AML was around 1%. [10] [11] [12] [13] [14] [15] In contrast, the JAK2-V617F mutation in AML secondary to MPD was in the range of 50%. 12, 14, 16 The question of whether the presence of the JAK2-V617F mutation favors leukemic transformation is currently unanswered. Due to the small number of patients with secondary AML, prospective studies are difficult to perform and the data is at present inconclusive. 17 Here we compared the JAK2-V617F status before and at leukemic transformation in 27 MPD patients and performed molecular studies on purified cell populations.
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Patients, Materials and Methods

Patients and samples
We performed a retrospective study on 27 patients with AML secondary to MPD (8 PV, 12 ET, 7 IMF) from whom samples at MPD and AML diagnosis were available.
Informed consent from all patients alive was obtained according to the Declaration of Helsinki. The study was conducted according to the guidelines of the local ethics committees at centers in France (Nantes, Dijon, Bordeaux) and Switzerland (Basel). The diagnosis of MPD was made according to the criteria of the World Health Organization (patients from Basel) or of the Polycythemia Vera Study Group (Nantes, Dijon, Bordeaux).
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Cell separations, RNA and DNA isolation Bone marrow or peripheral blood smears were scraped and DNA was isolated using the QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Leukemic blastss were isolated by fluorescence activated cell sorting (FACS) using side scatter and anti-CD34 antibodies or by laser capture microdissection of bone marrow films stained with MayGrünwald/Giemsa. Cells of the granulocytic lineage and T cells were sorted by FACS using anti-CD15 and anti-CD3 antibodies, respectively. Purity was > 95%. Preparations of DNA and RNA and cDNA syntheses were performed as described. 6, 21, 22 
Molecular analyses
The methods for detecting loss of heterozygosity on chromosome 9p (9pLOH) and for determining the copy number of chromosome 9p were described earlier. 4 A quantitative PCR assay for JAK2-V617F was performed with two different methods, 6 ,22 and analysis of clonality by X-chromosome inactivation in female patients heterozygous for a single nucleotide polymorphism in the MPP1 gene was assessed as described.
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Statistical analysis
To compare continuous variables among the groups we used the Mann-Whitney U-test.
Results and Discussion
We determined the JAK2-V617F mutation status by allele-specific PCR (AS-PCR) in 27 MPD patients (8 PV, 12 ET, and 7 IMF) from whom we obtained paired DNA samples at MPD diagnosis and leukemic transformation. At MPD diagnosis, the JAK2-V617F mutation was present in 17 of 27 patients (63%) ( Table 1) . Surprisingly, in 7 of these 17 patients the JAK2 mutation was undetectable in unfractionated peripheral blood or bone marrow samples at transformation to AML. Our AS-PCR assays have a detection limit of <1%T. 6, 22 In two additional patients we found that leukemic blast cells purified by FACS (patient DI-35) or laser capture microdissection (patient NA-48) were negative for JAK2-V617F, although the JAK2 mutation was detectable in unfractionated AML samples (Table 1) . Thus, 9/17 patients (53%) with JAK2-V617F positive MPD displayed JAK2-V617F negative leukemic blasts at diagnosis of AML. Purified granulocytes or CD15-positive myeloid cells obtained in 6 of these 9 patients were also negative for the JAK2 mutation, suggesting that the AML clone exerted a suppressive effect on the JAK2-V617F positive MPD clone (Table 1 ). In 5 patients (29%) we found JAK2-V617F both at MPD diagnosis and in leukemic blasts at transformation. In these 5 patients the allelic ratio of JAK2-V617F in blasts was greater than 50%T suggesting that at least a proportion of blasts were homozygous for JAK2-V617F. In the remaining 3/17 patients (18%) with JAK2-V617F positive MPD, the mutational status of the AML blasts could not be determined with certainty, due to lack of purified cells.
Patients positive for JAK2-V617F at MPD diagnosis who transformed to JAK2-V617F negative AML had a markedly shorter interval between diagnosis of MPD and leukemic transformation than those who transformed to JAK2-V617F positive AML (3±2 versus 10±7 years, n=14, p=0.013) (see supplemental Table S1 ). Information on treatment during the MPD phase was available in 25/27 patients (93%). Two patients transformed to AML without cytoreductive treatment, whereas the remaining patients received hydroxyurea (15), pipobroman (6) or other cytoreductive drugs (Table 1) . To address the question whether the MPD and AML clones in these patients arose de novo from different progenitor or stem cells, or represent subclones derived from a common ancestor, we performed molecular analyses in two cases. In one female patient with PV (NA-02), we compared clonality by 9pLOH and X-chromosomal inactivation pattern (XCIP) in purified cell populations at both stages of the disease (Figure 1 ). At diagnosis of MPD, this patient had 94%T and displayed 9pLOH ( Figure 1A) . Deletion of chromosome 9p was excluded by determining the copy number using quantitative PCR (supplemental Figure S1) . A phase resembling neutrophilic leukemia was observed in this 
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